This document is a USPTO patent application (US20260083733A1) for new dosage forms of a TYK2 inhibitor, identified as BMS-986165. The application, filed on December 2, 2025, describes formulations designed to be stable and bioavailable, specifically mentioning spray-dried dispersions within a solid polymer matrix. These formulations are intended for the treatment of autoimmune and auto-inflammatory diseases, including inflammatory bowel disease (IBD) and psoriasis.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future intellectual property and market exclusivity for specific drug formulations. Pharmaceutical and drug manufacturers involved in the development of TYK2 inhibitors or treatments for autoimmune diseases should monitor this application and related patents for competitive intelligence and potential licensing opportunities.